Sorry, you need to enable JavaScript to visit this website.
  • Branded drugs are more expensive because they’re newer, generally groundbreaking, and often for conditions that are difficult to treat. However, after a certain period of time, these same innovative medicines become generic medicines.

  • The difference between our approach and that of many other companies is that when a medicine becomes a generic, we still assume responsibility. Rather than focus on just what’s in development, we continue to closely monitor the quality, safety, and reliability of our generic medicines.

Science & Innovation

Harnessing the Power of AI to Detect ATTR-CM

Artificial intelligence (AI) has quietly become a part of our daily lives – through personalized recommendations, virtual assistants, or smart devices, we barely notice it anymore.
A young African - American doctor works on HUD or graphic display in front of her, we see her from the waist up in a modern laboratory thumbnail
Science & Innovation

In Search of a New Hemophilia Treatment

Despite significant advancements in hemophilia treatments over the past several decades, balancing management of the disorder while maintaining regular day-to-day activities remains a challenge.
Still from hemophilia video 2 thumbnail
Science & Innovation

Viral vs Bacterial Infections: Different Pathogens, Different Approaches

Learn about the key differences between viral and bacterial infections and the innovative prevention and treatment options being worked on for each type.
Woman sneezing into tissue thumbnail

The medicines available today have taken an average of 12 years to develop. With dedication, creativity, and science, we can significantly cut that time.

  • 00Phase 1
  • 00Phase 2
  • 00Phase 3
  • 00Registration
  • 00Total

Learn more about the process of joining a clinical trial and find a trial near you.

Go to Pfizer Clinical Trials Site Details